The type of ovarian cancer that is drawing researchers' attention is formally known as high-grade serous ovarian cancer, or HGSOC. Doctors also refer to it as epithelial high-grade serous ovarian ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. As we near the end of 2024, CURE is looking back at ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

Olaparib, a PARP inhibitor, shows promise as a maintenance therapy for patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD-positive but BRCA wild-type.

High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free ...